Compare Abeona Therapeutics Inc (ABEO) vs Crown Castle International Corp (CCI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Crown Castle International Corp — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while Crown Castle International Corp trades at $76.47 (market cap $33.70B). The key difference: Crown Castle International Corp is far larger — about 90.3× Abeona Therapeutics Inc's market cap, and Crown Castle International Corp pays a 5.5% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | CCI | |
|---|---|---|
Market Cap | $373.32M | $33.70B |
Sector | Health | Real Estate |
52-Week High | $7.23 | $113.91 |
52-Week Low | $4.17 | $74.92 |
Enterprise Value | $228.22M | $63.53B |
Dividend Yield | — | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Crown Castle (CCI) trades at $77.22, up 0.81% on the day, with a bearish technical outlook and mixed fundamentals. Recent earnings show a Q1 2026 miss but strong beats in prior quarters, while the company transitions to a pure-play U.S. tower focus after divesting its fiber business. Cash flow remains positive, but high debt levels and negative shareholder equity pose challenges. The stock is near its 52-week low, with a consensus price target of $97.33 suggesting significant upside potential.
The outlook for CCI hinges on execution of its strategic refocus and cost reductions. Opportunities include a 5.55% dividend yield and analyst optimism, but risks from elevated leverage and competitive pressures in telecom infrastructure warrant caution. Investor sentiment is divided, with technical indicators signaling near-term weakness despite long-term value arguments from bulls.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Crown Castle International Corp
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
Read more on CCI →
